Onkologie. 2020:14(5):219-220 | DOI: 10.36290/xon.2020.077
Immunotherapy in neoadjuvant setting
- Onkologická klinika, Fakultní nemocnice Olomouc
- Lékařská fakulta, Univerzita Palackého Olomouc
Immunotherapy has become new treatment option in oncology in the last decade. This treatment strategy has spread to many diagnosis. Excellent results were achieved, especially with checkpoint inhibitors, in patiens with metastatic disease has been studied in more than a hundred clinical trials with checkpoint inhibitors in neoadjuvant setting in patients with early stage disease. Promising results with well manageable adverse events has been evidenced in patients with malignant melanoma and breast cancer till now, these two diagnosis have already results from phase III clinical trials. However, more extensive trials will help us to find, if this way is the right way to go.
Keywords: neoadjuvat immunotherapy, immunotherapy, malignant melanoma, lung cancer.
Published: November 19, 2020 Show citation
References
- Tarhini AA , Edington H , Butterfield LH, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS ONE 2014; 9(2): e87705.
Go to original source... 
Go to PubMed... - Rozeman EA , Menzies AM , Van De Wiel B, et al. OpACIN-neo - a multicenter Phase II Study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO). Ann. Oncol. 2018; 29(Suppl. 8), Abstract LBA42. Go to original source...
- Blank CU, Versluis JM, Rozeman EA, et al. 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients-update of the OpACIN and OPACIN-neo trials. Presented at: 2020 AACR Virtual Annual Meeting; 2020: 22-24, Virtual. Abstract 3412. Go to original source...
- https://ascopost.com/News/59596, ESMO Immuno-Oncology 2018: OpACIN Trial: Neoadjuvant Ipilimumab Plus Nivolumab in Stage III Melanoma, By The ASCO Post, Posted: 12/20/2018 6:01:53 PM.
- https://clinicaltrials.gov/ct2/show/NCT03757689.
- Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. J Clin Oncol 35, 2017; (suppl; abstr 506). Go to original source...
- Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early Triple-Negative Breast Cancer, N Engl J Med 2020, doi: 10.1056/NEJMoa1910549. Go to original source... Go to PubMed...
- Gianni L, Huang C, Egle D, et al. Pathologic complete response to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study.